Again, this molecular lesion can be targeted in ERα negative breast cancer cell lines with co-treatments of VDR ligand (e.g. 1α,25(OH)2D3) plus HDAC inhibitors resulting in selective re-expression of VDR target genes, notably VDUP1 and GADD45A [24]. Here, VDR is linked to breast cancer.